StartUPDATES: New developments for healthcare startups
Read about news from Seven Bridges, Outcomes4Me, Carrum Health and more.
Read about news from Seven Bridges, Outcomes4Me, Carrum Health and more.
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.